Cowen Prime Advisors’s Niagen Bioscience NAGE Stock Holding History

Cowen Prime Advisors’s Portfolio NAGE Stock Details NAGE Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q2	$125K	Hold	79,557	–	–	0.04%	101
2023 Q1	$105K	Buy	79,557 +4,200	+6%	+$7.48K	0.04%	101
2022 Q4	$127K	Buy	75,357 +71,157	+1,694%	+$113K	0.05%	98
2022 Q3	$5K	Buy	4,200 +1,500	+56%	+$2.41K	﹤0.01%	160
2022 Q2	$5K	Buy	2,700 +600	+29%	+$1.17K	﹤0.01%	163
2022 Q1	$5K	Buy	+2,100	New	+$5.74K	﹤0.01%	164
2020 Q3	–	Sell	-2,700	Closed	-$5K	–	199
2020 Q2	$5K	Buy	2,700 +617	+30%	+$2.76K	﹤0.01%	163
2020 Q1	$7K	Sell	2,083 -117	-5%	-$449	﹤0.01%	168
2019 Q4	$9K	Buy	+2,200	New	+$7.82K	﹤0.01%	154
2019 Q1	–	Sell	-2,200	Closed	-$8K	–	190
2018 Q4	$8K	Buy	+2,200	New	+$7.64K	﹤0.01%	159
2018 Q3	–	Sell	-2,200	Closed	-$8K	–	213
2018 Q2	$8K	Buy	+2,200	New	+$8.36K	﹤0.01%	185

Other funds holding NAGE

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

TCM

Tieton Capital Management Yakima, Washington $348M AUM 45.13% 1-Year Est. Return

Iconiq Capital San Francisco, California $3.47B AUM 23.76% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return

GMT Capital Atlanta, Georgia $1.92B AUM 70.51% 1-Year Est. Return

Millennium Management New York $276B AUM 44.8% 1-Year Est. Return

GAMCO Investors Greenwich, Connecticut $11.1B AUM 41.79% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Cowen Prime Advisors's NAGE Position: Q2 2023 in Review

Cowen Prime Advisors held its Niagen Bioscience (NAGE) position steady in Q2 2023 at 79,557 shares worth $125K. The position accounts for 0.04% of the portfolio, ranked #101.

Cowen Prime Advisors first reported a position in NAGE in Q2 2018 and has held it in 11 quarters since. The position peaked at $127K in Q4 2022. 55 funds tracked by Wall St. Rank hold NAGE as of Q2 2023.

Cowen Prime Advisors held 79,557 shares of Niagen Bioscience worth $125K as of Q2 2023.
Cowen Prime Advisors left its Niagen Bioscience share count unchanged in Q2 2023.
Niagen Bioscience made up 0.04% of Cowen Prime Advisors's portfolio in Q2 2023, its #101 holding.
Cowen Prime Advisors first reported a position in Niagen Bioscience in Q2 2018 and has held it in 11 quarters since.
Cowen Prime Advisors's Niagen Bioscience position peaked at $127K in Q4 2022.
55 funds tracked by Wall St. Rank held Niagen Bioscience as of Q2 2023.

Based on Cowen Prime Advisors's 13F filing for Q2 2023, filed 31 Jul 2023.